<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Advanced Photonix Inc.</title>
	<atom:link href="http://www.stockbloghub.com/tag/advanced-photonix-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(PRGO) Perrigo Beats Earnings Forecast &#8211; Sales Miss</title>
		<link>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198</link>
		<comments>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198#comments</comments>
		<pubDate>Wed, 02 Nov 2011 21:04:32 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[JNJ]]></category>
		<category><![CDATA[Johnson & Johnson]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=86198</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.10 for the first quarter of fiscal 2012, beating the Zacks Consensus Estimate of $1.03 and the year-earlier earnings of 87 cents per share. Light sales performance was offset by a lower tax rate to drive earnings growth. First quarter revenues increased approximately 13% over the prior year to $725.3 million. Total revenues were, however, below the Zacks Consensus Estimate of $748 million. Strong performances by the Active Pharmaceutical Ingredients (API) and Rx Pharmaceuticals segments were offset by sluggish revenues from the company’s Nutritional and Consumer Healthcare businesses due to competitive pressures. The First Quarter of Fiscal 2012 in Detail The revenue performance in the quarter from four of the company’s businesses is detailed below. Consumer Healthcare (CHC): Perrigo reported CHC revenue ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/11/02/prgo-perrigo-beats-earnings-forecast-sales-miss/86198/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ORCL) Oracle and Google Set to Settle Claims</title>
		<link>http://www.stockbloghub.com/2011/09/12/orcl-oracle-and-google-set-to-settle-claims/82983</link>
		<comments>http://www.stockbloghub.com/2011/09/12/orcl-oracle-and-google-set-to-settle-claims/82983#comments</comments>
		<pubDate>Mon, 12 Sep 2011 17:19:28 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Application Software]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[AAPL]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Apple Inc.]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[CNOOC Limited]]></category>
		<category><![CDATA[GOOG]]></category>
		<category><![CDATA[Google Inc.]]></category>
		<category><![CDATA[Microsoft Corporation]]></category>
		<category><![CDATA[MSFT]]></category>
		<category><![CDATA[Oracle Corporation]]></category>
		<category><![CDATA[ORCL]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=82983</guid>
		<description><![CDATA[According to a recent report from news agency Bloomberg, Oracle Corp. (ORCL) and Google Inc. (GOOG) have agreed to attend a settlement discussion over the copyright- and patent-infringement lawsuit filed by Oracle last year. As per the order of the U.S magistrate, both the companies will be represented by their respective Chief Operating Officers (CEO). The settlement meeting is scheduled on September 19, 2011 and will be mediated by the U.S. Magistrate Judge. The attendance of the two CEO’s, Oracle’s Larry Ellison and Google’s Larry Page in the settlement meeting was strongly recommended in the September 8 court filing by the U.S. District Judge William Alsup, who is presiding over the case. The recommendation followed Oracle’s complaint regarding the failure of its out-of-court settlement efforts due to Google’s reluctance. In ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/09/12/orcl-oracle-and-google-set-to-settle-claims/82983/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Beats Second Quarter Earnings on All Fronts</title>
		<link>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033</link>
		<comments>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033#comments</comments>
		<pubDate>Thu, 28 Jul 2011 04:22:53 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[AstraZeneca plc]]></category>
		<category><![CDATA[AZN]]></category>
		<category><![CDATA[CEPH]]></category>
		<category><![CDATA[Cephalon Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=80033</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) second quarter 2011 earnings (excluding special items) of 52 cents per share were above the Zacks Consensus Estimate of 45 cents as well as the year-ago earnings of 37 cents per share. Earnings growth was driven by increase in generics revenue and improved gross margins. Quarter in Details Total revenues at Mylan climbed 15% over the prior year to $1.57 billion driven by increased sales of generic drugs and the positive impact of foreign exchange (Fx). Revenues were also ahead of the Zacks Consensus Estimate of $1.50 billion. Total revenues comprise both net revenues and other revenues from third parties. Mylan reports revenues through two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, Europe, Middle East &#38; Africa (EMEA), and ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/07/27/myl-mylan-beats-second-quarter-earnings-on-all-fronts/80033/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(API) Roche Holdings Partners with Evotec</title>
		<link>http://www.stockbloghub.com/2011/06/29/api-roche-holdings-partners-with-evotec/77707</link>
		<comments>http://www.stockbloghub.com/2011/06/29/api-roche-holdings-partners-with-evotec/77707#comments</comments>
		<pubDate>Wed, 29 Jun 2011 15:38:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Semiconductor - Integrated Circuits]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[BMY]]></category>
		<category><![CDATA[Bristol-Myers Squibb Company]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=77707</guid>
		<description><![CDATA[Roche Holdings Ltd. (RHHBY) recently announced a collaboration with Evotec AG for the development of oncology drugs. Under the agreement, Evotec will use its PhosphoScout platform to discover protein-phosphorylations, which will help in predicting favorable dosage and efficacy of targeted cancer drugs in patients. Furthermore, Roche will conduct clinical trials and evaluate the development of companion diagnostics for the purpose of patient stratification. Initially, for three years, Roche and Evotec will conduct multiple biomarker studies for therapeutic antibodies or small molecule inhibitors. We note that this deal with Evotec is the third this month for Roche. In early June, Roche entered into a licensing agreement with TeaRx Ltd., wherein it granted TeaRx the development and commercialization rights to treatments for patients at risk of thrombosis in Russia and 12 other ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/06/29/api-roche-holdings-partners-with-evotec/77707/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Cruises Past Estimates &#8211; Lifts Outlook</title>
		<link>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520</link>
		<comments>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520#comments</comments>
		<pubDate>Sun, 08 May 2011 15:51:27 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Merck & Company Inc]]></category>
		<category><![CDATA[MRK]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73520</guid>
		<description><![CDATA[Perrigo Company (PRGO) reported earnings per share of $1.07 for the third quarter of fiscal 2011, easily beating the Zacks Consensus Estimate of 96 cents and the year-earlier earnings of 81 cents per share. Results were driven by a solid top-line performance. Third quarter revenues increased 29% over the prior year to $692 million. Total revenues were also above the Zacks Consensus Estimate of $686 million. The year-over-year revenue growth was boosted by strong performances by the company’s generic prescription and active pharmaceutical ingredient (API) businesses. New products added $44 million to revenues. The Quarter in Detail The revenue performance in the quarter from four of the company’s businesses is detailed below. Consumer Healthcare (CHC): Perrigo reported CHC revenue of $425 million in the third quarter, up 13% over the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/08/prgo-perrigo-cruises-past-estimates-lifts-outlook/73520/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(MYL) Mylan Meets Analyst Estimates &#8211; Sales Upbeat</title>
		<link>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045</link>
		<comments>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045#comments</comments>
		<pubDate>Tue, 03 May 2011 18:03:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drugs - Generic]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan Inc.]]></category>
		<category><![CDATA[Novartis AG]]></category>
		<category><![CDATA[NVS]]></category>
		<category><![CDATA[Par Pharmaceutical Companies Inc]]></category>
		<category><![CDATA[PRX]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>
		<category><![CDATA[Watson Pharmaceuticals Inc.]]></category>
		<category><![CDATA[WPI]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=73045</guid>
		<description><![CDATA[Mylan Inc.’s (MYL) first quarter 2011 earnings (excluding special items) of 44 cents per share were in line with the Zacks Consensus Estimate. A higher quarterly tax rate, increased share count and pricing pressure in Europe offset the increase in generics revenue in North America to deliver in line earnings growth. Earnings were nevertheless 22% above year-ago earnings of 36 cents per share. Quarter in Details Total revenues at Mylan climbed 12.1% over the prior year to $1.45 billion driven by increased sales of generic drugs. Revenue was also barely above the Zacks Consensus Estimate of $1.44 billion. Total revenues comprises both net revenues and other revenues from third parties. Mylan reports revenues from two segments: Generics and Specialty. Generic third party net sales, derived from sales in North America, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/05/03/myl-mylan-meets-analyst-estimates-sales-upbeat/73045/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(PRGO) Perrigo Resolves Manufacturing Issues with FDA</title>
		<link>http://www.stockbloghub.com/2011/04/13/prgo-perrigo-resolves-manufacturing-issues-with-fda/71384</link>
		<comments>http://www.stockbloghub.com/2011/04/13/prgo-perrigo-resolves-manufacturing-issues-with-fda/71384#comments</comments>
		<pubDate>Wed, 13 Apr 2011 22:00:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Related Products]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Perrigo Company]]></category>
		<category><![CDATA[PRGO]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=71384</guid>
		<description><![CDATA[Perrigo Company (PRGO) recently announced the resolution of manufacturing issues at its Allegan, Michigan facility with the US Food and Drug Administration (FDA) following conclusion of re-inspection of the facility by the agency. The FDA commenced a re-inspection of the facility in early March 2011. The FDA concluded that the Allegan facility now meets the regulatory standards, thus removing a major overhang on Perrigo. Perrigo can now look for approval of any export license or generic drug applications for products manufactured from the facility. Approval of products, due to be manufactured at the Allegan facility, like the generic version of Mucinex was being held up due to the FDA warning letter. Following the resolution of the letter, we believe that approval of such generics will be expedited. In April 2010, ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/13/prgo-perrigo-resolves-manufacturing-issues-with-fda/71384/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(AMSC) American Superconductor Corporation Analyst Downgrades Shares to Underperform</title>
		<link>http://www.stockbloghub.com/2011/04/07/amsc-american-superconductor-corporation-analyst-downgrades-shares-to-underperform/70862</link>
		<comments>http://www.stockbloghub.com/2011/04/07/amsc-american-superconductor-corporation-analyst-downgrades-shares-to-underperform/70862#comments</comments>
		<pubDate>Thu, 07 Apr 2011 14:07:35 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Diversified Electronics]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[American Superconductor Corporation]]></category>
		<category><![CDATA[AMSC]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Ceradyne Inc.]]></category>
		<category><![CDATA[CRDN]]></category>
		<category><![CDATA[Polypore International Inc]]></category>
		<category><![CDATA[PPO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=70862</guid>
		<description><![CDATA[We downgrade our recommendation for American Superconductor Corporation (AMSC) from Neutral to Underperform. Our downgrade is inspired by the refusal of its largest customer &#8211; Sinovel Wind Group Co. Ltd to accept further shipments. Sinovel is China&#8217;s largest and the world&#8217;s third largest wind turbine manufacturer. American Superconductor would be paying a high price for its over-dependence on Sinovel. On March 31, 2011, Sinovel bogged down by high inventory levels refused to accept contracted shipments of 1.5 MW and 3 MW wind turbine core electrical components and spare parts from American Superconductor. Sinovel also was unable to pay for past shipments worth $56 million. Sinovel represented approximately 75% of American Superconductor’s total revenue for the nine month period ending December 31, 2010. American Superconductor expects the situation to continue till ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/04/07/amsc-american-superconductor-corporation-analyst-downgrades-shares-to-underperform/70862/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Reports Earnings That Beat The Street</title>
		<link>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982</link>
		<comments>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982#comments</comments>
		<pubDate>Wed, 12 May 2010 21:29:23 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[Sanofi-Aventis]]></category>
		<category><![CDATA[SNY]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=36982</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) first quarter earnings of 91 cents per American Depository Share (ADS) was well above the Zacks Consensus Estimate of 89 cents and the year-ago earnings of 71 cents. Teva’s top-line performance remained strong with revenues increasing 16% to $3.7 billion. Strong sales of Copaxone and generics helped drive revenues. The Quarter in Detail Revenue performance across key business segments was mixed. While the Pharmaceuticals segment performed well thanks to strong performances in the North American, European and international segments, the Active Pharmaceutical Ingredients (API) segment reported a 13.7% decline in growth with sales coming in at $139 million. Pharmaceutical segment revenues were driven by strong performances in the North American, European and international segments. The launch of a generic version of Mirapex and continued strong sales ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/05/12/teva-teva-pharmaceutical-industries-reports-earnings-that-beat-the-street/36982/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Misses Earnings by a Penny</title>
		<link>http://www.stockbloghub.com/2010/02/17/teva-teva-pharmaceutical-industries-misses-earnings-by-a-penny/28240</link>
		<comments>http://www.stockbloghub.com/2010/02/17/teva-teva-pharmaceutical-industries-misses-earnings-by-a-penny/28240#comments</comments>
		<pubDate>Wed, 17 Feb 2010 22:49:18 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[ADS]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[Alliance Data Systems Corporation]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=28240</guid>
		<description><![CDATA[Teva Pharmaceutical Industries’ (TEVA) fourth quarter earnings of 94 cents per American Depository Share (ADS) missed the Zacks Consensus Estimate by a cent. Earnings, however Incorporatedreased 18% from the year-ago period. Annual earnings were in line with the Zacks Consensus Estimate at $3.37 per ADS, up 11%. Teva’s top-line performance remained strong with fourth quarter revenues increasing 33% to $3.8 billion and 2009 revenues coming in at $13.9 billion, up 25%. The strong top-line performance was offset by higher operating expenses which led to the earnings miss in the fourth quarter. Fourth Quarter in Detail Strong sales of Copaxone and the respiratory business helped drive revenues in the reported quarter. Net revenues increased 33% to $3.80 billion, with the Barr acquisition contributing to revenues across different geographical segments. Exchange rate ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/02/17/teva-teva-pharmaceutical-industries-misses-earnings-by-a-penny/28240/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(IDC) Interactive Data Corporation Releases New Product</title>
		<link>http://www.stockbloghub.com/2009/12/02/idc-interactive-data-corporation-releases-new-product/21753</link>
		<comments>http://www.stockbloghub.com/2009/12/02/idc-interactive-data-corporation-releases-new-product/21753#comments</comments>
		<pubDate>Wed, 02 Dec 2009 21:39:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Information & Delivery Services]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[IDC]]></category>
		<category><![CDATA[Interactive Data Corporation]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=21753</guid>
		<description><![CDATA[A leading provider of financial market data, analytics and related solutions, Interactive Data Corporation (IDC) announced that its Fixed Income Analytics business has released BondEdge Asset Manager. The BondEdge Asset Manager is designed to assist portfolio managers manage relative risk and reward of investment versus leading fixed income indices and liability benchmarks. IDC continuously refreshes its product lines in order to stay competitive. In 2009, IDC’s Fixed Income Analytics business unveiled BondEdge Fixed Income Strategist, designed for risk reporting and trade analysis. BondEdge Fixed Income Strategist is available via the BondEdge Next Generation Platform, which is built on the Microsoft NET Framework and provides a highly intuitive, flexible user interface. IDC had earlier released a new application programming interface (API) for its BondEdge service. These new capabilities are bundled with ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/02/idc-interactive-data-corporation-releases-new-product/21753/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(TEVA) Teva Pharmaceutical Industries Reports Strong Quarter</title>
		<link>http://www.stockbloghub.com/2009/11/04/teva-teva-pharmaceutical-industries-reports-strong-quarter/19689</link>
		<comments>http://www.stockbloghub.com/2009/11/04/teva-teva-pharmaceutical-industries-reports-strong-quarter/19689#comments</comments>
		<pubDate>Wed, 04 Nov 2009 22:09:37 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Advanced Photonix Inc.]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Inc.]]></category>
		<category><![CDATA[MYL]]></category>
		<category><![CDATA[Mylan]]></category>
		<category><![CDATA[TEVA]]></category>
		<category><![CDATA[Teva Pharmaceutical Industries Limited]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=19689</guid>
		<description><![CDATA[Teva Pharmaceutical Industries Ltd. (TEVA) reported earnings of 89 cents in the third quarter of 2009, up 16% from the year-ago period and a cent above the Zacks Consensus Estimate. Strong sales of Copaxone and in the respiratory business helped drive earnings in the reported quarter. Net sales increased 25% to $3.55 billion, with the Barr acquisition contributing to sales across different geographical segments. The strengthening U.S. dollar adversely impacted net sales by $160 million or 6%. Revenue performance across key business segments was mixed. While the Pharmaceuticals Sales segment posted growth of 27% with revenues coming in at $3.4 billion, the active pharmaceutical ingredients (API) segment reported an 8% decline in growth with sales coming in at $136 million. Pharmaceutical segment sales were driven by strong performances in the ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/11/04/teva-teva-pharmaceutical-industries-reports-strong-quarter/19689/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

